Dr. Domchek Discusses Areas of Investigation in Breast Cancer

Susan Domchek, MD
Published: Wednesday, Apr 04, 2018



Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses areas of investigation in breast cancer.

Things that physicians are looking at as predictors of response to chemotherapy include how many tumor-infiltrating lymphocytes (TILs) are at baseline and what the immune cells are, says Domchek. Additionally, physicians are also looking at expression of PD-L1 in the tumor to hopefully give a clear picture of who will respond.

It might also be that certain characteristics of the tumor, including DNA damage repair and homologous recombination defects, may give physicians a clue to these questions. However, it is challenging and physicians still need to sort through all of this information, explains Domchek.
 


Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses areas of investigation in breast cancer.

Things that physicians are looking at as predictors of response to chemotherapy include how many tumor-infiltrating lymphocytes (TILs) are at baseline and what the immune cells are, says Domchek. Additionally, physicians are also looking at expression of PD-L1 in the tumor to hopefully give a clear picture of who will respond.

It might also be that certain characteristics of the tumor, including DNA damage repair and homologous recombination defects, may give physicians a clue to these questions. However, it is challenging and physicians still need to sort through all of this information, explains Domchek.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x